Find policies, billing codes, payers, states, and providers
Pediatric Preventive Screening
Customize your policy alerts
Sign up for Oscar Health Policy AHS-G2006-Diabetes alerts
Get alerted when Policy AHS-G2006-Diabetes changes without checking for updates manually.
Monitor payer policy activity
Defines coverage stance and clinical guidance for laboratory-based preventive screening tests for individuals newborn through age 18 (excluding genetic newborn screening panels which are addressed separately). Affects providers submitting claims to Oscar Health for pediatric preventive screening services.
No material clinical or coverage changes in this revision.
Coverage Criteria for Pediatric Preventive Screening
Newborn and routine pediatric screenings meeting criteria
The following screenings MEET CRITERIA when applied per the described population and frequency:
State-specific mandates apply; see Applicable State and Federal Regulations
See Note 1 for CDC-defined risk factors
See Note 2 for AAP-defined risk factors
See Note 3 for AAP TB risk factors
See Note 4 for AAP/NLA risk factors and indications (including familial hypercholesterolemia)
Coverage stance by guideline and risk
Coverage follows evidence-based recommendations from cited authorities; specific screening decisions depend on age and risk factors as noted by guideline sources.
References: USPSTF statements cited in policy.
AAP and other specialty guidance may recommend risk-based or age-specific screening despite USPSTF 'insufficient evidence' determinations.
Policy references CDC, AAP, AAFP, NLA recommendations for risk-based approaches.
Newborn screening panels are not uniform nationwide. Each state determines the specific conditions included in its newborn screening program, and state-required tests may differ from the federal Recommended Uniform Screening Panel (RUSP). The policy recognizes that RUSP lists core and secondary conditions that many programs adopt, but implementation and mandated tests are set at the state level and therefore vary by jurisdiction.
The policy reflects the USPSTF finding that evidence is insufficient to support routine universal screening for lipid disorders in children and adolescents ≤20 years. Consistent with USPSTF and family medicine guidance, the policy favors evidence-based, risk-targeted approaches rather than blanket universal lipid screening for all pediatric patients.
Examples of pediatric screening areas the USPSTF has judged to have insufficient evidence for routine universal application include: screening for lipid disorders in children and adolescents ≤20 years; screening for elevated blood lead levels in asymptomatic children ages 1–5 years; screening for primary hypertension in asymptomatic children and adolescents; and screening for iron deficiency anemia in children ages 6–24 months.
When the USPSTF labels evidence as insufficient, it means the balance of benefits and harms cannot be determined for routine, population-wide screening. For policy application, this implies that routine universal screening is not supported as a default; instead, testing should be guided by age-specific recommendations from pediatric authorities (for example, AAP/Bright Futures) and by individual or population risk factors. The policy therefore supports risk-based or targeted screening strategies for these conditions rather than routine universal testing.
Procedure Codes, Thresholds, and Reference Values
| 80061 | Lipid panel; must include cholesterol total (82465), HDL direct (83718), triglycerides (84478) |
| 82247 | Bilirubin; total |
| 82248 | Bilirubin; direct |
| 82465 | Cholesterol, serum or whole blood, total |
| 83020 | Hemoglobin fractionation and quantitation; electrophoresis (eg, A2, S, C, and/or F) |
| 83021 | Hemoglobin fractionation and quantitation; chromatography (eg, A2, S, C, and/or F) |
| 83655 | Lead |
| 83718 | Lipoprotein, direct measurement; high density cholesterol (HDL cholesterol) |
| 84439 | Thyroxine; free |
| 84443 | Thyroid stimulating hormone (TSH) |
| 86481 | Tuberculosis test, cell mediated immunity antigen response measurement; enumeration of gamma interferon-producing T-cells |
| 86580 | Skin test; tuberculosis, intradermal |
| 88720 | Bilirubin, total, transcutaneous |
| S3620 | Newborn metabolic screening panel (includes test kit, postage and state-specified laboratory tests) |
Provider Responsibilities and Billing Guidance
Authorization and medical necessity
Services described in this policy are covered only when they meet authorization and medical necessity requirements for the procedure, diagnosis, and the member’s state of residence; coverage does not guarantee reimbursement and may be affected by member benefit documents and provider contracts.
- Coverage decisions are subject to authorization and medical necessity criteria.
- Other factors (legislative mandates, provider contracts, member benefit documents) may modify reimbursement determinations.
Procedure code billing guidance
Bill services using the applicable CPT or HCPCS codes listed in this policy for the specific laboratory tests performed; the policy names the procedure codes to use when filing claims.
Maintain accurate clinical and billing records
Providers must submit accurate documentation of the services performed and ensure coding reflects the service rendered; retain source records that support medical necessity and the billed codes.
- Documentation must follow industry-standard coding guidelines (CPT, HCPCS, ICD-10, NDC, DRG, CMS NCCI/CCI edits).
- Accurate records may be requested to substantiate claims and reimbursement.
Operational provider instructions
Use operational best practices to ensure correct code selection, timely submission, and alignment with member benefit and contract rules to avoid delays or denials.
- Verify member benefits and contract terms prior to claim submission.
- Confirm lab panels are billed with the specific CPT/HCPCS codes listed in this policy.
Required documentation and coding
Submit claims with the supporting clinical documentation that demonstrates the indication, age/risk criteria, and frequency consistent with this policy when applicable (for example, lead testing schedules or one-time dyslipidemia windows).
- Document the clinical indication and risk factors that justify testing per policy criteria (e.g., CDC/AAP lead risk factors, dyslipidemia risk or age windows).
- For newborn metabolic screening, bill the appropriate newborn panel HCPCS (S3620) per state-specified tests.
Claims must reference listed CPT/HCPCS codes
Ensure each claim includes the applicable CPT/HCPCS procedure codes listed in the policy that correspond to the laboratory tests performed; failure to reference the listed codes may lead to processing errors.
Risk of denial or recoupment for coding errors
Claims may be denied or subject to recoupment if coding/billing guidelines or current reimbursement policies (including CCI/NCCI edits) are not followed; accurate coding and documentation are required to support payment.
- Noncompliance with industry-standard coding guidelines can result in denial or recovery of payment.
- Follow CMS and CMS NCCI/CCI guidance where applicable.
State or federal government policy precedence
If a conflict exists between this policy and any applicable government policy (e.g., LCD, NCD, or state Medicaid), the government policy takes precedence and will be used to make coverage determinations.
- Check applicable Medicare (CMS) and state Medicaid policies for updates that may supersede this policy.
- Government policy precedence may result in different coverage/claims outcomes for affected members.
Background and Rationale
Preventive screening in pediatrics aims to protect and promote health across newborns, children, and adolescents by detecting treatable conditions early and guiding appropriate interventions. The American Academy of Pediatrics’ Bright Futures periodicity schedule frames many age-specific laboratory recommendations (for example: newborn blood and bilirubin testing; anemia screening at 12 months with prior risk assessment at four months; lead risk assessment and testing at specified intervals when indicated; and dyslipidemia screening with targeted age windows and risk assessments). These guidance sources are used alongside USPSTF determinations to shape coverage and to prioritize risk-based screening where universal evidence is lacking.
Key Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.